ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental implant market, today announced it will report financial results for the second quarter of 2025 and file its Quarterly Report on Form 10-Q after market close on Wednesday, July 30, 2025.
On July 21, 2025, ZimVie issued a press release announcing its entry into a definitive agreement pursuant to which ZimVie will be acquired by an affiliate of ARCHIMED (“ARCHIMED”) for $19.00 in cash per share. A copy of that press release is available in the “Investor Relations” section of ZimVie’s website.
The transaction is expected to close by year-end 2025, subject to customary closing conditions, including approval by ZimVie’s stockholders and receipt of applicable regulatory approvals. Upon completion of the transaction, ZimVie will become a privately held company, and shares of ZimVie common stock will no longer be listed or publicly traded on the Nasdaq Stock Exchange. Due to the pending transaction, ZimVie will not host a conference call for the second quarter and is withdrawing its fiscal 2025 guidance. ZimVie’s previous financial guidance should not be relied upon.
About ZimVie
ZimVie is a global life sciences leader in the dental implant market that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to support dental tooth replacement and restoration procedures. From its headquarters in Palm Beach Gardens, Florida, and additional facilities around the globe, ZimVie works to improve smiles, function, and confidence in daily life by offering comprehensive tooth replacement solutions, including trusted dental implants, biomaterials, and digital workflow solutions. As a worldwide leader in this space, ZimVie is committed to advancing clinical science and technology foundational to restoring daily life. For more information about ZimVie, please visit www.ZimVie.com.
Participants in the Solicitation
ZimVie and its directors, executive officers, and other members of management and employees may, under SEC rules, be deemed to be “participants” in the solicitation of proxies from ZimVie stockholders in connection with the proposed transaction with Zamboni Parent, Inc., an affiliate of ARCHIMED. Information about ZimVie’s directors and executive officers is set forth in ZimVie’s Proxy Statement on Schedule 14A for its 2025 Annual Meeting of Shareholders, filed with the SEC on March 25, 2025 (the “2025 Proxy”). Please refer to the sections titled “Compensation of Non-Employee Directors,” “Executive Compensation,” and “Security Ownership of Directors and Executive Officers” in the 2025 Proxy. To the extent holdings of ZimVie securities by directors or executive officers have changed since the amounts disclosed in the 2025 Proxy, those changes have been or will be reflected in Forms 3 or 4 filed with the SEC.
This includes Form 4s filed by: Richard Heppenstall on March 11 and May 19, 2025; Vafa Jamali on March 11, March 27 (twice), April 3, and May 19, 2025; Indraneel Kanaglekar on March 11, May 19, and July 3, 2025; Heather Kidwell on March 11 and May 19, 2025; Richard Kuntz on April 2, May 9, and July 2, 2025; Vinit K. Asar, Sally Crawford, and Karen Matusinec on May 9, 2025. Additional details regarding the interests of these participants will be included in ZimVie’s proxy statement related to the proposed transaction, when available.
Additional Important Information
This press release may be deemed solicitation material in connection with the proposed acquisition of ZimVie by Zamboni Parent, Inc., an affiliate of ARCHIMED. In connection with the proposed transaction, ZimVie intends to file relevant materials with the SEC, including proxy statements in preliminary and definitive form. Investors and stockholders of ZimVie are urged to read all relevant documents filed with the SEC, including ZimVie’s proxy statement (if and when available), because they contain or will contain important information about the proposed transaction. These documents will be available free of charge at the SEC’s website (www.sec.gov) and from the Investor Relations section of ZimVie’s website (https://investor.zimvie.com), or upon request from ZimVie Investor Relations.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws. These include statements regarding expectations, intentions, strategies, and prospects, which are based on current management beliefs and assumptions. Forward-looking statements are identified by terms such as “may,” “will,” “expects,” “believes,” “plans,” “targets,” “intends,” “guidance,” and similar expressions. Actual outcomes may differ materially due to various risks and uncertainties, including but not limited to: the risk that the transaction may not be completed; failure to obtain stockholder or regulatory approval; emergence of competing offers; the effects of the transaction on relationships with customers, suppliers, and employees; failure to retain talent; changes in financial or business performance; supply chain challenges; regulatory changes; cyberattacks; changes in tax law; and impacts of global economic or health-related disruptions. A detailed discussion of these and other factors is included in ZimVie’s filings with the SEC.
